PTGDR
Prostaglandin D2 receptor
As of the edition of 20 October 2026, PTGDR (prostaglandin D2 receptor, UniProt Q13258) has 3 drugs tested at it and 3 companies on the list, 3 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q13258
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 8
- Disease areas
- Nutrition and metabolism; Lungs and airways; Immune system; Inherited and neonatal; Hormones; Ear, nose and throat; Heart and blood vessels; Infections
- Registered trials of its drugs
- 32
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 1 |
| Stopped | 1 |
| Withdrawn from market | 1 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Laropiprant | Withdrawn from market | Phase 4 | none listed |
| Vidupiprant | Went quiet | Phase 2 | none listed |
| Asapiprant | Stopped | Phase 2 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Total on the list | 3 |
The other 0 companies at PTGDR
In the product3 companies in all; 0 are not named here, and no score is.
See the 3 companies at PTGDR, ranked, with the facts behind eachRequest access. Nothing is shown until you do.